The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | ADJUBIL: durvalumab and tremelimumab in resectable BTC
Thorsten Goetze, MD, The University Cancer Center Frankfurt, Frankfurt, Germany, comments on the Phase II ADJUBIL trial (NCT05239169) of durvalumab and tremelimumab with or without capecitabine in the adjuvant setting for resectable biliary tract cancer (BTC). Recurrence-free survival at one year was higher in the immunotherapy-only arm, which also had a more favorable safety profile. These results suggest potential benefit of immunotherapy alone over combination with capecitabine. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
